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ABSTRACT 
BTK inhibitors have induced high response rates in the treatment of leukemias and 
lymphomas. Ibrutinib is the first-in-class US Food and Drug Administration (FDA)-approved 
BTK covalent inhibitor to treat chronic lymphocytic leukemia (CLL). However, a sub-group 
of patients develops resistance to ibrutinib therapy. The most common resistance mechanism 
is substitution of cysteine 481 to serine of BTK, the residue to which ibrutinib binds 
irreversibly. Few other amino acid replacements at this site had been characterized. In paper 
I, we therefore performed functional analysis of all the possible amino acid replacements at 
C481 site due to a single nucleotide change. We also included threonine substitution because 
of its structural similarity to serine. BTK with cysteine-to-threonine substitution retains 
catalytic activity and cause ibrutinib resistance. Thus, we identified a new potential resistant 
variant, BTK C481T for BTK irreversible inhibitors. For the replacement with arginine, 
phenylalanine, tryptophan or tyrosine, BTK enzymatic activity was completely ablated, while 
glycine substitution still showed some kinase activity, but to a much lower extent. 
CLL patients receiving ibrutinib treatment show rapid mobilization of tumor cells from 
lymph nodes (LN) to peripheral blood (PB). However, the detailed mechanism of ibrutinib-
induced tumor cell redistribution has not been clarified. In paper II, we tried to explore this 
observation by analyzing changes in plasma inflammation-related biomarkers, transcriptional 
levels in CLL cells, B-cell activation and migration markers, and PB mononuclear cell 
populations as early as 9h after ibrutinib treatment. We compared the changes between before 
and at 6 time points after treatment initiation in LN and PB. We observed a significant 
downregulation of 10 plasma inflammation-related markers, mainly chemokines but not 
CLL-derived within 9 hours. RNA-sequencing data showed significant and continuous 
expression changes of genes related to B-cell receptor (BCR) signaling and CLL biology. We 
conclude that ibrutinib rapidly blocks an ongoing inflammatory response and in particular 
influences LN CLL cells.  
Loss-of-function (LOF) mutations of BTK lead to a severe block in B lineage development, 
as seen in X-linked agammaglobulinemia (XLA). In paper III, we analyzed a large number of 
XLA patients, including 108 previously unreported cases. The tolerance to single amino acid 
replacements was predicted for full-length BTK. Moreover, we compared these germline 
XLA-causing mutations with those acquired in leukemia and lymphoma. Based on published 
cases and those reported to a mutation database, BTK mutation spectrum in more than 10,000 
BTK-independent tumors was compared to the BTK-dependent malignancies, CLL and 
mantle cell lymphoma (MCL), and also to BTK-potentially-dependent malignancies, like 
diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and germinal center 
(GC)-derived B-cell lymphoma. This analysis for the first time identifies BTK to be a 
potential tumor suppressor in a subset of DLBCL and FL. Therefore, whether BTK inhibitors, 
which show highly efficient therapeutic effects in CLL and MCL, might promote 
tumorigenesis in a subset of other B cell malignancies remains an open question.  
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1 INTRODUCTION 
1.1 PRIMARY IMMUNODEFICIENCY DISEASES (PIDS) 
The group of primary immunodeficiency diseases (PIDs) contains numerous genetic 
disorders that influence various components of the innate and adaptive responses1. The first 
description of a PID with information about the underlying mechanism was reported in 1952 
when X-linked agammaglobulinemia (XLA) was discovered by Ogden Bruton2, which will 
be discussed in detail in the next section. After the discovery of XLA, more than 350 unique 
immunodeficiency disorders have been characterized. Primary B-cell deficiencies account for 
two-thirds of PIDs, and the most severe form, which leads to reduction of immunoglobulins 
(Igs) of all isotypes is called agammaglobulinemia. There are two major types of 
agammaglobulinemia, XLA and autosomal recessive agammaglobulinemia (ARA). 
In the majority of patients with PIDs, the most common observation is deficiency in the 
antibody production3. The characteristic of both XLA and ARA is increased susceptibility to 
bacterial infections, the most prevalent being respiratory and/or gastrointestinal tract 
infections. The infection occurs often in the first year of life after the disappearance of the 
maternal IgG4. In both XLA and ARA, B-lymphocytes and plasma cells are dramatically 
reduced, but the number and phenotype of other cell lineages are usually normal. It is highly 
suggestive that the differentiation disorder is only confined to the B-cell lineage. This 
characterization distinguishes XLA and ARA from many other antibody deficiencies, which 
not only have the defect of B-lymphocytes, but also are often accompanied by T-lymphocyte 
deficiencies and autoimmunity5–7. 
Currently, the treatment for PID patients is intravenous and subcutaneous administration of 
immunoglobulin and antibiotic therapies. The human agammaglobulinemia with a known 
defective genetic component is summarized in Table 1. Since the characteristics of both XLA 
and ARA are similar, the investigation of the gene mutations would facilitate diagnosing 
diseases and also explore appropriate treatments for patients.  
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    Table 1. Human agammaglobulinemia with a known defective genetic component. 
GENE SYMBOL PROTEIN INHERIANCE 
BTK8 Bruton tyrosine kinase XLA 
BLNK9,10 B-cell linker protein ARA 
CD79A9,11 B-cell antigen receptor complex-
associated protein alpha 
ARA 
CD79B12,13 B-cell antigen receptor complex-
associated protein beta 
ARA 
IGHM9,14–16 Immunoglobulin Heavy Constant 
Mu 
ARA 
IGLL19,17 Immunoglobulin lambda-like 
polypeptide 1 
ARA 
PIK3R118 Phosphatidylinositol 3-kinase 
regulatory subunit alpha isoform 1 
ARA 
In conclusion, the mutations of genes coding for the pre-B cell receptor (pre-BCR)/BCR or 
downstream molecules related with these receptors cause agammaglobulinemia in humans 
(Figure 2)4. However, the genes summarized in Table 1 are at normal status in many patients 
with agammaglobulinemia. Considering the large number of downstream components 
associated with pre-BCR/BCR, new mutations are expected to be identified among the 
downstream molecules. It seems to be reasonable to propose that mutations in genes coding 
for further downstream molecules of the pre-BCR/BCR will not cause ‘pure’ 
agammaglobulinemia, since they are also frequently expressed in other cell types involved in 
different signaling pathways4. 
 
1.1.1 B-lymphocyte development 
In humans, B-cell development is a highly regulated procedure, which starts from 
hematopoietic stem cells (HSCs) in the bone marrow. There are several stages during the 
development, pro-B cell, pre-B cell, immature B-cell and mature B-cell. The first section of 
B-lymphocyte development occurring in the bone marrow, includes pro-B cell to immature 
B-cell stages. These immature cells can be easily eliminated upon interaction with self-
antigens. Immature B-lymphocytes express high IgM and low IgD (IgMhigh/IgDlow). When 
the cells exit from the bone marrow and enter to the peripheral environment, the immature B-
cells become mature and express IgG, low IgM and high IgD (IgMlow/IgDhigh)19,20. Mature B-
cells can migrate to the second lymphoid tissues, where they can differentiate into memory B-
lymphocytes or plasma cells21. 
In the bone marrow, at the early stage of B-cell development, there is a unique mechanism of 
genetic rearrangement called V(D)J recombination. This procedure rearranges variable (V), 
diversity (D) and joining (J) gene regions, which eventually results in the antigen-binding 
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segments of Igs. Human antibodies are composed of heavy chains and light chains, which 
harbor both constant (C) and variable (V) regions. In the B-cell development, the first 
recombination event is D-J recombination and then followed by linking to V gene segment, 
which forms a rearranged VDJ gene complex ultimately resulting in the production of the 
IgM heavy chain. The recombination is similar in the light chain, except lacking a D segment. 
The assembly of the heavy chain with one of the light chains leads to the formation of IgM 
that can be found on both immature and mature B-cells22.  
In mature B-cells, antigen binding to BCR induces a series of signaling events that ultimately 
activate some transcription factors, such as nuclear factor kappa B (NF-κB) and activator 
protein 1 (AP-1). These transcription factors can regulate expression of the genes which are 
related with B-cell survival, differentiation and activation23–25. However, BCR can still 
transduce a constitutive signaling in a low level even without antigen binding and this process 
is called tonic signaling. Tonic signaling is also required for B-cell survival, which has been 
illustrated by the finding that ablation of BCR expression in vivo in mice induces rapid B-cell 
apoptosis26. 
 
1.1.2 X-linked agammaglobulinemia (XLA) 
As described above, XLA is a hereditary PID due to mutations of the Bruton tyrosine kinase 
(BTK) gene, which encodes a nonreceptor tyrosine kinase27. The BTK gene localizes to the 
short arm of the X chromosome in the 21.3-22 region (Xq21.3-Xq22)28–30. The structure and 
expression of the BTK protein will be discussed in details later. In XLA patients, the numbers 
of B-lymphocytes are dramatically decreased due to the block of B-cell development, which 
leads to low serum Igs of all isotypes31,32. As a consequence, patients with XLA are very 
susceptible to bacterial and enteroviral infections and the most typical infections are from 
Haemophilus influenza and Streptococcus pneumonia33,34. 
XLA essentially only occurs in males whereas females are usually healthy even carrying 
XLA-causing BTK mutations. This is because the non-random X chromosome inactivation 
cells that express normal BTK have selective advantage35.  The incidence for XLA has been 
estimated to be 1:200,000. There is a high appearance of this X-linked disease in males and 
they are easily diagnosed at molecular and clinical levels. The corresponding spontaneous 
disease for XLA in mice is called X-linked immunodeficiency (Xid) and it is much milder 
than XLA36. Xid in mice is caused by the cysteine substitution at the Arg28 site in the PH 
domain37, which is one of the most frequently mutated amino acids in BTK. 
 
1.1.3 BTKbase 
The human proteome contains around 500 protein kinases. Among these protein kinases, 
BTK has the largest number of disease-causing mutations38. A big amount of mutations in 
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BTK can induce XLA, which includes amino acid substitution, nonsense mutation, frameshift 
mutation caused by insertion or deletion, and splice-site mutation. XLA-causing mutations 
are compiled in a database called BTKbase, which was established in 1994 and this online 
resource is being updated continuously39–41. In 2005, our group published a review 
summarized the mutations. At that time there were 554 unique molecular events included in 
the BTKbase42. Along with the data updating, a total number of 1800 of public variants 
representing 920 unique public DNA mutants have been recorded in the BTKbase currently41. 
For each patient, the following information (if available) is incorporated to the database: the 
identification of the entry, a detailed characterization of the mutation with the corresponding 
reference, explanation of the mutation at different levels, and distinct parameters from 
patients8. 
XLA-causing mutations have been reported in all the domains and also in the noncoding 
regions of the BTK gene. All types of mutations are distributed throughout the whole BTK. 
Among all the reported XLA-causing mutations, amino acid substitutions are predominant, 
and account for two-thirds of all mutations. Amino acid replacements are scattered all over 
the whole BTK except for the Src homology 3 (SH3) domain. So far, only two amino acid 
substitutions in this domain have been found to cause XLA41,43. Amino acid substitutions 
appear in the kinase domain (KD) with the highest frequency, which is probably because the 
KD contains several highly conserved regions that are important for the BTK catalytic 
activity44. 
Among all the amino acids, arginine is the most frequently mutated amino acid due to that 
some arginine codons contain the CpG-doublet45. CpG dinucleotides are mutational hotspots 
and are found in four out of the six codons for arginine. Thereby, arginine is the most often 
replaced residue by other amino acids. Mutations of arginine can also give rise to a stop 
codon, by a CGA to TGA change causing XLA due to the production of an unstable, missing 
protein. Totally, there are four such CGA codons in BTK, Arg13, Arg255, Arg520 and 
Arg52542. At these four positions, nucleotide substitutions could also generate stop codon 
leading to XLA. However, the mutation scenarios are different among the four sites. So far, at 
residues Arg13 and Arg255, only stop codons have been reported to cause XLA, whereas no 
XLA-causing missense mutations have been identified. Comparing with Arg520 and Arg525, 
it is highly suggestive that amino acid replacements could be tolerated at Arg13 and Arg255 
(P<0.001)42. It is well known that arginine is the residue with the highest mutation frequency 
because of the mutational hotspot. Arginine may also be difficult to replace due to its 
elongated and charged side chains having many functional and structural interactions45. On 
the other hand, substitution with proline is found to be the most common XLA-causing 
replacement42, presumably because this substitution frequently disturbs protein conformation, 
thereby altering both stability and function of BTK. 
In addition, amino acid substitutions occurring in secondary structural elements are more 
likely to cause disease than those found in loop regions. This phenomenon is probably due to 
the higher flexibility in loops than in helices and strands. In the wild-type BTK, the relative 
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solvent-accessible surface (SAS) value is a good indicator for the solvent accessibility at each 
site44.Therefore, residues could be classified into three categories: buried, exposed and 
intermediate44. This classification facilitates predicating the pathogenicity of amino acid 
substitutions. In general, the majority of buried sites are highly conserved whereas most 
exposed residues are weakly conserved. Variations at conserved and buried residues are the 
most frequently disease-causing because substitutions at these sites are prone to affect protein 
stability. Similarly, those small amounts of conserved exposed residues are associated with 
pathogenicity strongly44.  
One of the initial purposes of BTKbase was to study the mutation characteristics and try to 
build up the genotype–phenotype correlations8. Although this connection has not been 
demonstrated, it should be kept in mind that almost all the identified patients manifest the 
classical severe pattern of the disease with only a few exceptions. For example, as for amino 
acid substitution, replacements by related amino acids are expected to cause a milder form of 
disease. Therefore, the definitive genotype–phenotype relationship was predicted to be exist, 
but further investigation is needed42. In addition, the mutation types might influence the 
disease severity such as the mutations in less conserved regions e.g., amino acid replacements 
in non-invariant positions or splicing defects, which might still induce partial production of 
BTK and cause milder XLA9,42. 
So far, a big amount of BTK mutations have been found to cause XLA and are recorded in 
the BTKbase. Some novel mutations would also show up in the future. Therefore, it is really 
crucial to maintain the BTKbase, which collects all the known mutations and will be 
continuously updated along with the increasing exploration of this field. The BTKbase has 
been applied in different studies, such as phenotype-genotype correlations as discussed above 
and the prediction of the pathogenicity, which facilitates analyzing and diagnosing diseases, 
and developing the precise medicines as well44. 
 
1.2 PROTEIN TYROSINE KINASES (PTKS) 
1.2.1 The TEC family of tyrosine kinases 
The TEC family kinases (TFKs) are the second-largest group of nonreceptor PTKs. They are 
critical components in several signal transduction pathways that mediate cell development, 
differentiation, proliferation and apoptosis. The TFKs consist of five members; BTK, TEC, 
IL2-inducible T-cell kinase (ITK), resting lymphocyte kinase (RLK/TXK) and bone marrow 
tyrosine kinase gene in chromosome X protein (BMX)46.  
The expression pattern among the TFKs varies, but all except for BMX are primarily  
appearing in the hematopoietic cells27,46–52. BTK is constitutively expressed in all 
hematopoietic cells except for T-lymphocytes and plasma cells47. Tec is expressed in B- and 
T- cells, myeloid cells, and endothelial cells53,54. ITK is the highest expressed TFKs member 
in T-cells and also exists in natural killer (NK) cells and mast cells49,55. ITK deficiency in 
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humans causes susceptibility to serious, often lethal, Epstein–Barr virus (EBV) infection56. 
RLK/TXK has been reported to be expressed in the T-lymphocytes, preferentially in Th1 
cells, and NK cells51,55. BMX was initially identified in the bone marrow but mainly seems to 
exist in endothelial cells48. In some lineages, more than one TFK member is expressed. For 
instance, both BTK and TEC are found in B-cells, whereas ITK and RLK/TXK express in T- 
cells. Moreover, these kinases are also found to be expressed in other species, such as 
Drosophila melanogaster57 and zebra fish58. 
The structure of all the five TFK members is similar. It consists of pleckstrin homology (PH) 
domain at the N-terminus, followed by Tec homology (TH), SH3, SH2 domains and KD. 
However, the structure of RLK/TXK is an exception with a unique region containing a 
palmitoylated cysteine string in the N terminus59 (Figure 1).  
 
Figure 1. Schematic diagram of the domain structure of TFK members (modified from46). 
The N-terminal PH domain mediates binding to the membrane, whereas, in TXK, the 
palmitoylated cysteine string has a similar function as the PH domain. The TH domain 
consists of a highly conserved zinc binding BTK motif60,61 and followed by a Proline-rich 
region. In BMX, the residues surrounding the Proline-rich region are not conserved as in 
other TFKs, thus it is referred as a “TH like” domain46. The SH3 domain is involved in 
managing protein-protein interactions which are crucial for various signal transduction 
processes62. Similar with the SH3 domain, the SH2 domain also regulates protein interaction 
but involves in myriad phosphotyrosine (pY)-signaling pathways63.  Unlike other members, 
the SH3 domain in BMX is truncated, therefore, it is called “SH3 like” domain46. The kinase 
domain at the C-terminus is essential for the kinase activity in all TFK members. 
 
1.2.2 BTK 
As described in the previous chapter, BTK belongs to the TFKs and it is a crucial molecule in 
B-cell development, differentiation and proliferation. BTK consists of 659 amino acids and 
its molecular weight is 77 kDa. BTK expression starts from early stage of B-cell development 
and it can be found among all the stages before plasma cells47,64,65. In XLA, BTK mutations 
cause a partial block at the pro- to the pre-B cell stage, as well as, a completely 
developmental block at the mature B-lymphocyte stage (Figure 2A)31,32. Correspondingly, in 
Xid mice, there is a later and only partial B-cell developmental block between the pre-B and 
mature B-cell stage (Figure 2B)36,66.		
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A. 
 
B.  
 
Figure 2. A schematic representation of B-lymphocyte blockage in XLA (A) and in Xid (B). 
It is well known that BTK is a cytoplasmic non-receptor tyrosine kinase. However, BTK can 
also be detected in the nucleus67,68. Moreover, it is reported that the nucleocytoplasmic 
shuttling of BTK is mediated by the interaction with ankyrin repeat domain 54 (ANKRD54) 
and the interaction is SH3 dependent69. A paper published by our group suggested that the 
nucleus exit of both BTK and another TFK, TXK is mediated by ANKRD54 and it depends 
on the SH3 domain entirely69. In the cytoplasm, BTK plays a pivotal role in the BCR 
signaling pathway, whereas, the role of BTK in the nucleus is poorly understood. It has been 
demonstrated by one group of researchers that the DNA binding of a B-cell transcription 
factor, Bright (B-cell regulator of Ig heavy chain transcription), was dependent on the 
presence of BTK67. 
BTK is a crucial component involved in BCR signaling pathway, which regulates survival 
and proliferation of both normal cells and malignant cells. This will be discussed in details in 
the next chapters. However, few reports also proposed that BTK could function as a tumor 
suppressor70–72. It was found that BTK could act as a tumor suppressor when cooperated with 
a homozygous loss-of-function (LOF) of the B-cell linker protein BLNK/SLP-65 in pre-B 
cells and this was independent of BTK catalytic activity in the animal model70,71. In addition, 
there have also been a few literatures from patients suggesting an influence of the BTK 
gene72–74. For example, Rada, M., et al have proposed that BTK functions as a tumor 
suppressor via stabilizing p53 protein expression72. The p53 protein is one of the most potent 
tumor suppressors and it could increase the BTK expression. This suggests that the 
relationship between BTK and p53 is regulated by a positive feedback loop, with the eventual 
goal of strengthening p53 activity upon damage responses72. 
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1.2.3 B-cell receptor (BCR) pathway 
As described previously, BCR signaling is essential for B-cell differentiation, proliferation 
and apoptosis. The BCR is a transmembrane receptor protein, which is constituted by two 
identical IgL chains, two identical IgH chains and the heterodimer co-receptor Iga (CD79A) 
and Igb (CD79B)75,76. Both Iga and Igb contain the immunoreceptor tyrosine-based 
activation motifs (ITAMs) at the cytoplasmic tail, which play a crucial role in signal 
transduction75,77. 
Upon B-cell receptor activation, the tyrosine residues in ITAMs are phosphorylated by the 
SRC-family protein tyrosine kinase such as LCK/YES novel tyrosine kinase (LYN), which 
create docking sites for spleen tyrosine kinase (SYK)78. BTK translocates to the plasma 
membrane via interactions between its PH domain and the phosphatidylinositol-3,4,5-
triphosphate (PIP3) which is generated by phosphatidylinositol-3-kinase (PI3K)79. 
Meanwhile, the SRC-family kinases, in particular LYN and SYK are activated, resulting in 
transphosphorylation of Y551 in BTK which promotes the BTK enzymatic activity and 
subsequently auto-phosphorylates the Y223 in the SH3 domain80,81. Accordingly, PLCg2 is 
phosphorylated and activated82. A signalosome of multiple protein tyrosine kinases and 
adaptor proteins consisting of SYK, BTK, BLNK and PLCg2 is formed and results in the 
calcium mobilization and protein kinase C (PKC) activation24,83–85. This is followed by the 
activation of various transcription factors, which regulate B cell survival or apoptosis, 
proliferation, and differentiation86. 
The BCR is critical for normal B-cell development and maintenance. Meanwhile, BCR 
signaling is also a pivotal pathway that promotes progression of B-cell malignancies87,88. 
Therefore, the development of specific inhibitors targeting components involved in the BCR 
signaling pathway holds promising to treat B-cell malignancies, which we will discuss in the 
following chapters. 
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Figure 3. The schematic representation of BCR signaling pathways (modified from86).  
 
1.3 B CELL MALIGNANCIES 
1.3.1 Chronic lymphocytic leukemia (CLL) 
CLL is a type of chronic lymphoid malignancy for which the growth of B-lymphocytes is out 
of control and cells are resistant to apoptosis. In CLL, CD5+CD23+ monoclonal B-cells are 
accumulated in primary and secondary lymphoid organs. CLL mainly occurs in elderly 
people, with a median age of over 70-years at the time of diagnosis and the incidence in 
males is twice as in females89.  
The symptoms, and physical and laboratory findings in CLL patients are various at the time 
of diagnosis. Some patients are diagnosed as having CLL due to the enlargement of lymph 
nodes. It usually occurs in the cervical area, where the swelling decreases and increases 
spontaneously but does not disappear completely. Based on a high white blood cell count, 
particularly a large accumulation of circulating lymphocytes by a regular blood test, many 
patients have no symptoms when diagnosed with CLL89,90.  
In general, CLL is originated from autoreactive germinal center (GC) B-lymphocytes with 
constitutive BCR activation91–94. BCR is crucial for the proliferation and survival of normal B 
lymphocytes as mentioned before. Most B-cell lymphoproliferative disorders have functional 
surface BCR expression, including CLL. Depending on the mutational condition of the BCR, 
CLL can be classified into two types, heavy-chain variable region gene-unmutated (IgV-
unmutated) CLL (UM-CLL) and IgV-mutated CLL (M-CLL)91,95. It has been suggested that 
the M-CLL originates from antigen-experienced B-lymphocytes which have went through the 
GC of secondary lymphoid tissues, where the Ig somatic hypermutation occurs96. However, 
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whether UM-CLL is derived from GC-independent antigen-experienced B-lymphocytes or 
naïve B-cells is still unknown96.  The gene expression profiling between CLL samples and 
subpopulations of untransformed human B-cells was compared, which showed that both UM-
CLL and M-CLL cells had similar features with CD27+ memory B-lymphocytes96. This 
suggests that these two CLL subtypes are derived from antigen-experienced CD27+ memory 
B-lymphocytes, but UM-CLL and M-CLL originate from GC-independent or post-GC cells, 
respectively96,97. However, other report has suggested that UM-CLL is derived from 
CD5+CD27− naive B-cells whereas M-CLL resembles CD5+CD27+ post-GC subset98. In 
general, the suggestion about M-CLL presumably originates from GC-experienced B-
lymphocytes whereas UM-CLL derives from pre-GC-naive B-lymphocytes or GC-
independent memory B-lymphocytes still remains on debate99.  
The disease is more aggressive in patients with UM-CLL than patients with M-CLL100. 
Previous studies reported that M-CLL patients experienced longer overall survival (OS) than 
UM-CLL patients100,101. Patients with M-CLL had a median OS of over 20 years while those 
with UM-CLL only had median OS of 8 years. Moreover, other gene mutations such as TP53 
resulting in p53 inactivation, is also a high risk factor in CLL patients leading to shorter 
OS102–104. 
The initial treatments for CLL patients vary depending on the situation of patients, such as 
the exact diagnosis and the progression of the disease. The treatments include chemotherapy, 
bone marrow transplantation, radiation therapy or biological therapy. However, there is no 
disease progression in a small group of patients throughout their lifetime and therefore 
therapy is not required for them. But a substantial group of patients will eventually need 
treatment due to active CLL105.  
In this thesis, we concentrated on the biological therapy, which also called 
chemoimmunotherapy. Before treatment, some prognostic molecular markers are required to 
be identified in CLL patients, which are useful for assessing the individual risk of CLL 
progression. This information can provide recommendations for designing appropriate 
individualized therapy programs. The risk factors contain mutational status of TP53 and the 
BCR IGHV genes as discussed above, cytogenetic abnormalities for instance del(11q), 
del(13q), del(17p), and trisomy 12. CLL patients harbor high-risk molecular and/or 
cytogenetic features, which are those with TP53 disruption, UM-CLL, del(11q), or del(17p), 
and correspondingly, low-risk patients have M-CLL, del(13q) and trisomy 12.  
In treatment naïve CLL patients who require therapy, the presence of del17p and TP53 
disruptions should be tested is a general consensus99. Patients with mutated TP53 and/or 
del17p are mostly recommended to be given the BTK inhibitor, ibrutinib, as the upfront 
treatment106. Whereas, for those patients who are not suitable for ibrutinib treatment because 
of some comorbidities or drug interactions, the B-cell lymphoma 2 (BCL-2) inhibitor, 
venetoclax is an excellent option107. In patients with wild-type TP53, the IGHV mutational 
status and physical conditions need to be considered for individualized treatment. In the high-
risk group of patients with UM-CLL, regardless of comorbidities and age, ibrutinib therapy in 
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the first-line setting is a growing consensus99. However, the treatment for low-risk CLL will 
still be on debate until more data are obtained from ongoing randomized clinical tests99. 
 
1.3.2 BTK inhibitors 
1.3.2.1 First generation 
1.3.2.1.1 Ibrutinib 
Kinase inhibitors have a huge impact on cancer therapy, and inhibitors for BTK have 
revolutionized the treatment of leukemias and lymphomas over the last few years108. Ibrutinib 
is the first approved BTK inhibitor by FDA to treat several malignancies. The generation of 
ibrutinib originated from a series of small molecule inhibitors of BTK, which were 
synthesized in 2007 by Pan, Z., et al109. Ibrutinib, also called  PCI-32765, was selected from 
many BTK inhibitors for further clinical trials because it showed high specificity and efficacy 
for inhibiting BTK activity in experimental models109. This compound exhibited increasingly 
clinical activity in several B-cell lymphomas and has been FDA-approved to treat 
malignancies, including CLL110, mantle cell lymphoma (MCL)111, marginal zone lymphoma 
(MZL)112, Waldenström macroglobulinemia (WM)113 and graft-versus-host disease114. 
Currently, ibrutinib is the only approved BTK inhibitor for CLL treatment, in both the front-
line and relapsed and/or refractory (R/R) disease conditions. 
Ibrutinib binds to a conserved cysteine residue (Cys481) at the ATP binding site of BTK 
covalently and irreversibly, and thus block BCR signal transduction115–117. As mentioned 
above, in addition to be approved to treat several B-cell lymphomas, ibrutinib also showed 
encouraging preclinical efficacy to apply on autoimmune and inflammatory disorders118,119.  
After oral administration, ibrutinib is absorbed rapidly and reach the maximum serum 
concentration, around 0.4 µM in one to two hours110. Since ibrutinib binds to BTK covalently 
and irreversibly, it can be given to patients once daily with the dose of 420mg even though 
the half-life of this compound is short (4-6 hours)110,120. 
As described above, ibrutinib is the first FDA-approved BTK inhibitor to treat CLL. 
However, with the long-term follow-up investigation, it has shown that up to 51% of patients 
have suspended ibrutinib treatment due to its intolerance and complications121–124. The 
common adverse effects of ibrutinib therapy are diarrhea, bleeding events, infections, 
arthralgia, dermatologic events, and hypertension121,125–129. There are also some additional 
rare side effects including atrial fibrillation, pneumonitis, neutropenia and major hemorrhage.  
These adverse effects could arise from off-target binding of ibrutinib because it has a 
potential to inhibit activity of other tyrosine kinases which contain similar cysteine residue at 
the ATP binding position. These tyrosine kinases include BLK, BMX, epidermal growth 
factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), HER4, ITK, 
Janus kinase 3 (JAK3), TEC and TXK117,130,131. For instance, the prevalence of bleeding is up 
 12  
to 44% and it is known that BTK, along with other members of the TFKs, are involved in 
platelet aggregation through glycoprotein VI signaling132. Therefore, the inhibition of on-
target of BTK and off-target of other TFKs by ibrutinib is the potential mechanism for 
bleeding events occurred in patients.  
In addition, diarrhea is the most prevalent ibrutinib-related side effect with 50% occurrence in 
patients128,133–135. The suggested mechanism of ibrutinib-related diarrhea is off-target binding 
to EGFR, since it is known that diarrhea is an adverse effect observed with EGFR 
inhibitors136. 
Moreover, ibrutinib could also affect other proteins without cysteine residue, like 
PTK6/BRK, C-terminal Src Kinase (CSK), FRG, hematopoietic cell kinase (HCK) and 
lymphocyte-specific protein tyrosine kinase (LCK), which might influence the efficacy or 
induce adverse effects of ibrutinib118,131. Therefore, toxicity is a common issue related with 
long-term treatment of ibrutinib, thus it is the main reason for discontinuous therapy of this 
compound. 
 
1.3.2.1.2 Affect malignant B-cells and tumor microenvironment (TME) cells 
In tissues, like lymph node or bone marrow, CLL cells proliferate at different 
microanatomical sites which are called proliferation centers or pseudo follicles137,138. CLL 
cells are dependent on external signals from the TME for their survival and evolution. CLL 
cells normally experience spontaneous apoptosis when they are cultured in vitro. Tissue 
stromal cells, for instance bone marrow stromal cells (BMSC) could prevent spontaneous and 
drug-induced CLL cell apoptosis in a contact-dependent manner139,140. The interactions 
between stromal cells and CLL cells occur both in bone marrow and in secondary lymphatic 
compartments in CLL patients141.  In lymph nodes, CLL cells interact with various kinds of 
stromal cells, like CD4+ T cells and CD68+ nurse like cells (NLCs), which could also protect 
CLL cells from apoptosis142–145. Stromal cells constitutively secret chemokines and also 
transduce additional signals, which regulate CLL cell tissue homing, survival and 
proliferation138. Conversely, stromal cells are also activated by CLL cells via inducing PKC-
b2 expression and subsequently activating NF-kB pathway146. In addition, NLCs, which are 
found in lymphoid tissues from CLL patients, can secrete chemokines like CXCL12 and 
CXCL13 to attract and protect CLL cells142,147,148. The interaction between NLCs and CLL 
cells via the expression of a proliferation-inducing ligand (APRIL) and the TNF family 
members B-cell activating factor (BAFF) on NLCs, protects CLL cells from apoptosis149. In 
CLL animal model, it has been demonstrated that NLCs can promote CLL disease 
progression150,151.  
In TME, CLL cells affect the composition and function of T-cells and NK cells in order to 
escape from immune-mediated cytotoxicity152. In CLL patients, the expression of inhibitory 
receptors such as programmed-death-receptor 1(PD-1) was found to be upregulated on T cells 
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and the number of CD4+CD25high T regulatory cells (Treg) was increased in the TME152. 
These alterations might facilitate the evasion from anti-tumor immunity. Moreover, the 
phenotype of CD8+ cytotoxic T-cells was also changed and formed defective immune 
synapses because both granzyme B packaging and degranulation have been impaired153. In 
CLL patients, both the response to soluble BCL2 associated athanogene 6 (BAG6) ligand 
secreted by CLL cells and the activating receptor NKp30 on NK cells were reduced in CLL 
patients, which restricted the NK cell–mediated antitumor activity154,155. CLL cells and their 
TME are depicted in Figure 4156.  
In CLL patients, the absolute lymphocyte count (ALC) increased temporarily after ibrutinib 
treatment, which is so-called “redistribution lymphocytosis”. The ALC reduced rapidly 
during the off-drug period but went up again when patients restarted to take ibrutinib110. This 
observation, similar to all compounds targeting the BCR signaling, is due to the migration of  
lymphocytes from nodal tissues. And this migration is probably because the signaling 
disruption that affects adhesion factors in LNs and bone marrow, causes cell mobilization157. 
As discussed before, upon BCR engagement, BTK is rapidly activated by LYN and SYK, 
leading to the activation of downstream signaling which regulates B-cell proliferation and 
differentiation. Therefore, block of BTK activity by ibrutinib inhibits CLL cell survival and 
proliferation. In addition to BCR signaling, BTK is also implicated in signaling pathway of 
other receptors such as adhesion molecules (integrins) and CXCR4 and CXCR5 chemokine 
receptors, which are associated with B-lymphocyte adhesion and migration as shown in 
Figure 4156,158. In CLL patients receiving ibrutinib therapy, the drug also inhibits integrin-
mediated adhesion and chemotaxis towards CXCL12 and CXCL13159,160. Interestingly, 
Ponader, S., et al found that the secretion of CCL3 and CCL4, being BCR activation-
dependent chemokines in plasma, was downregulated both in vitro and in vivo from CLL 
patients receiving ibrutinib treatment159. In conclusion, ibrutinib inhibits CLL cell 
proliferation, migration and homing by affecting both CLL cells and the TME cells. 
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Figure 4. The CLL microenvironment. (A) The interaction between CLL cells and bone 
marrow stromal cells (BMSC) and nurse like cells (NLCs). (B) CLL cells and their 
interaction with T-cells and NK cells, which support CLL cell survival and proliferation. 
Adapted from ten Hacken E, et al. Clin Cancer Res. 2014. Reprinted with permission from 
publishers. 
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1.3.2.1.3 Resistance mechanisms for ibrutinib 
The malignant cells developing resistance to the targeted treatments is the principal issue that 
restricts the efficacy of the therapy. Although ibrutinib shows good effectiveness in several 
B-cell malignancies, there are still a substantial group of patients who do not respond to it and 
some patients treated with ibrutinib develop resistance. Different ibrutinib resistance 
mechanisms have been summarized in Figure 5122,161–168.  
 
Figure 5. The summary of different ibrutinib resistance mechanisms in B-cell cancers. 
Mutations of the molecules which are involved in the B-cell signaling pathway are the most 
frequent mechanisms of developing resistance to ibrutinib. Most mutations occur in BTK or 
its direct downstream molecule PLCγ2169. The most common mechanism of ibrutinib 
resistance in B-cell malignancies is cysteine-to-serine substitution at residue 481(C481S) in 
BTK, which accounts for more than 80% in resistant patients162,170,171. Within this 
substitution, the covalent binding of ibrutinib to BTK will be destroyed, which changes the 
irreversible inhibition to reversible inhibition and also reduces the binding affinity to BTK161.  
In addition to the BTK C481S mutation, various PLCγ2 mutations have also been reported to 
be involved in ibrutinib resistance in CLL patients. Woyach, J. A., et al found that in six 
ibrutinib-resistant CLL patients, three different PLCγ2 mutations were detected in two CLL 
patients, arginine-to-tryptophan mutation at site 665 (R665W), serine-to-tyrosine mutation at 
site 707 (S707Y) and leucine-to-phenylalanine at site 845 (L845F)162,171. Different from the 
BTK C481S mutation, which results in ultimate loss of BTK inhibition by ibrutinib, all the 
PLCγ2 mutations are gain-of-function mutations. These PLCγ2 mutations could induce the 
activation of BCR signaling constitutively and are not inhibited by ibrutinib. Some other 
BTK variations related with BTK C481S mutation or PLCγ2 mutations have also been found 
in few patients. These BTK mutations include T474I, T474S, C481F, C481G, C481R, 
C481Y and L528W, all of which occur in the catalytic kinase domain122,172,173. Moreover, a 
new mutation in the SH2 domain of BTK, threonine-to-alanine mutation at position 316 
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(T316A) has been identified in ibrutinib resistant CLL patients174. However, the resistance 
mechanism of this mutation is still unknown. 
Currently, all these mutations occur before or during treatment is still on debate175. The most 
common view is that resistant BTK or PLCγ2 mutations exist at the baseline before drug 
exposure in ibrutinib-treated CLL. However, the numbers of mutant CLL sub-clones are too 
small to be detected. Notably, highly sensitive technologies (such as droplet microfluid 
technologies) have been developed and applied to facilitate detecting these mutations before 
ibrutinib treatment initiation. This supports the idea that external selection pressure coming 
from targeted treatment promotes the selection of rare sub-clones that are already existed 
prior to treatment170. 
 
1.3.2.2 Second generation BTK inhibitors 
Even though ibrutinib shows ideal effectiveness in patients, due to the development of 
resistance and its off-target adverse effects, second generation of BTK inhibitors have been 
developed, which has improved binding specificity and maintained effects against mutated 
BTK variants 176,177. Several other BTK inhibitors are currently being tried either singly or in 
combination, both in the frontline and the R/R conditions. 
Acalabrutinib (ACP-196) is a new selective second generation BTK inhibitor, which has 
higher specificity than ibrutinib and it was approved by FDA for the treatment of MCL in 
2018. Acalabrutinib seems to have less adverse effects than ibrutinib because of its much 
high specificity. This compound also binds to Cys481 covalently and irreversibly176,177. Even 
though acalabrutinib shows high overall response rate (ORR) in patients with R/R disease, 
whether this drug is more efficient than ibrutinib still needs a further follow-up177. There is an 
ongoing phase III study which compares acalabrutinib with ibrutinib.  
Another BTK inhibitor, vecabrutinib (SNS-062) seems to have good efficacy and inhibits 
BTK activity in vitro in CLL cells harboring BTK C481S resistance mutation178. Several 
other BTK inhibitors such as CC-292 (Spebrutinib), BGB-3111 (Zanubrutinib), ONO/GS-
4059 (Tirabrutinib) and so on are currently under evaluation for the treatment of lymphomas 
and autoimmune diseases. BTK inhibitors are summarized in Table 2. 
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Table 2. The summary of BTK inhibitors, which are tested in lymphomas and autoimmune 
diseases. 
BINDING 
TYPE 
BTK INHIBITORS STATUS 
 
COVALENT 
Ibrutinib CLL, MCL, MZL, WM, GVHD-FDA 
ACP-196 (Acalabrutinib) 
MCL-FDA;  
CLL, WM, RA-Phase II 
CC-292 (Spebrutinib) 
RA-Phase II; 
CLL-Phase I 
BGB-3111(Zanubrutinib) 
MCL-FDA; 
CLL, WM-Phase III 
CT-1530 CLL, MCL-Phase I/II 
ONO/GS-4059 (Tirabrutinib) 
CLL, WM-Phase II; 
RA-Phase I 
M7583 BCL-Phase I/II 
ICP-022 (Orelabrutinib) 
WM-Phase II;  
CLL, MCL-Phase I/II; 
RA-Phase I 
TG-1701 CLL-Phase I 
ABBV-105 RA-Phase II 
TAS5315 RA-Phase II 
SHR1459 CLL-Phase I 
NON-
COVALENT 
BMS-986142 RA-Phase II 
SNS-062 (Vecabrutinib) CLL-Phase I/II 
DTRMWXHS-12 MCL-Phase I 
RN-486 CLL-Preclinical 
GDC-0853 (Fenebrutinib) RA-Phase II 
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2 AIMS 
The overall aim of this thesis is to address the effect of BTK activity inhibition and BTK 
mutations in different diseases. In CLL patients, BTK inhibitor, ibrutinib prevents tumor cell 
survival by disrupting mainly BCR signaling and also affects other cell populations which 
regulate cell migration and homing. Ibrutinib binds to the site of Cys481 in the BTK kinase 
domain, for which serine substitution is the most common resistance mechanism in patients. 
Whether other potential amino acid replacement at C481 by nucleotide changes would cause 
resistance is unknown. Moreover, LOF mutations of BTK cause XLA in males and the 
mutation spectrum is still under investigation. The individual aims related to each paper are 
listed as following. 
 
Paper I 
• To identify other BTK mutations at Cys481 that could induce ibrutinib resistance. 
• To characterize all the possible BTK mutations at the ibrutinib binding site. 
 
Paper II 
• To investigate the change of inflammation biomarkers in plasma in CLL patients with 
ibrutinib therapy. 
• To characterize the early effect of ibrutinib in patients in various cell populations in lymph 
node and peripheral blood. 
• To explore the dynamics of ibrutinib-induced transcriptional alterations in CLL patients. 
 
Paper III 
• To make predictions on the tolerance to amino acid replacements in BTK. 
• To validate several unreported BTK variants in a cellular context by assaying their catalytic 
activity. 
• To investigate BTK mutations in three groups of malignancies, BTK-dependent tumors, 
BTK-independent tumors and BTK-potentially-dependent tumors. 
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3 MATERIALS AND METHODS 
The following chapters briefly describe some relevant methods used in this thesis. More 
details about the methods can be found in the respective papers. 
 
3.1 CELL SOURCES 
In paper I, to investigate the stability and catalytic activity of different BTK variants, several 
cell lines were used. The cell lines include non-lymphoid cell lines such as COS-7 (African 
green monkey fibroblast-like kidney) and HEK-293T (human embryonic kidney cells), as 
well as lymphoma origin cells, DT40 (chicken lymphoma cells). Two out of the three cell 
lines were purchased from the American Type Culture Collection. The DT40 with inactivated 
BTK cell line, B7.10 was generated by Dr T. Kurosaki’s laboratory, Japan, and generously 
provided to us179. In paper II, all the experiments were performed in primary cells sorted from 
patient samples. In paper III, COS-7 and HEK-293T cell lines were used to assess the 
catalytical activity of several BTK variants. 
 
3.2 PLASMID TRANSFECTION 
In both paper I and paper III, plasmids with respective BTK mutations were transfected into 
cell lines. Two transfection techniques were performed in this thesis depending on the 
characteristics of cell lines. For adherent cells, COS-7 and HEK-293T cells, plasmids were 
transfected by using polyethylenimine (PEI) (Polyscience, Inc., Warrington, PA, USA). 
Whereas, for suspension cell type, B7.10 cells, we used electroporation to transfect plasmids 
by the Neon transfection system according to the manufacture’s protocol (Life technologies, 
La Jolla, CA, USA).  
 
3.3 PROTEIN ANALYSIS 
3.3.1 Western blot (WB) 
In both paper I and III, we analyzed the BTK expression and activity of different variants by 
WB and compared it with wild-type BTK. Protein was extracted from transfected cells and 
mixed with sample buffer (0.4M sodium carbonate, 0.5M ditiothreitol, 8% SDS and 10% 
glycerol) and then heated for 5 minutes at 65°C.The mixture was loaded onto a 4-12% Bis-
Tris Protein gel and run at MES SDS running buffer at 120V for around 2 hrs. After this, the 
iBlot system was used to transfer the proteins on the gel to a nitrocellulose membrane. 
Membranes were incubated with blocking buffer for 1 hr at room temperature (RT) and 
followed by the incubation with primary antibody at 4°C overnight. The membranes were 
washed and then incubated with secondary antibodies for 45 minutes at RT. After this, 
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membranes were washed again and then scanned using the Odyssey infrared imaging system 
(Li-COR Biosciences GmbH). 
3.3.2 Immunoprecipitation (IP) 
In paper I, in order to obtain purified BTK and PLCg2, IP was performed. IP is a common 
technique to isolate and purify proteins from heterogeneous protein mixtures. Cells were 
lysed in lysis buffer and then protein mixture was extracted. The protein mixture was 
incubated with the corresponding antibody that binds to the targeted protein. After 
incubation, the interacted antibody-protein mixture was pulled down by protein A/G beads to 
isolate the targeted protein. This method is also applied to identify protein-protein 
interactions. 
 
3.4 IN VITRO KINASE ASSAY 
In paper I, in order to demonstrate whether PLCg2 was the direct substrate of BTK, in vitro 
kinase assay was performed. This technique can detect the catalytic activity of a kinase in a 
purified form instead of in whole cell lysates. BTK and  PLCg2 were purified and isolated by 
IP firstly. Subsequently, wild-type BTK or BTK variant protein was incubated with PLCg2 
and ATP in the kinase reaction buffer for 30 minutes at 30°C. This specific buffer enables 
BTK to transfer a phosphate group (the gamma-PO4) from ATP to PLCg2. The reactions 
were suspended by adding sample buffer and followed by WB analysis. 
 
3.5 PATIENT SAMPLE ANALYSIS 
3.5.1 Peripheral Blood Mononuclear Cell (PBMC) Isolation 
In paper II, peripheral blood (PB) and lymph node (LN) samples from CLL patients were 
collected before treatment and at a series of timepoints after treatment initiation. Firstly, PB 
samples were spun down at 500g for 5 mins to obtain plasma, which was frozen at -80°C for 
later analysis. The left blood was mixed with DPBS and followed by the density gradient 
centrifugation using Ficoll-Hypaque gradient (GE Healthcare, Uppsala, Sweden) to isolate 
PBMCs.  
 
3.5.2 Flow Cytometry 
Flow cytometry is a routinely used technique to detect physical and chemical characteristics 
of a population of cells. By incubating with specific antibody mixture, different populations 
of cells could be sorted out separately. This technique is one of the main methods used 
throughout the paper II.  
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Mononuclear cells were first blocked with FcR and then stained for 30 minutes at 4°C with a 
group of antibodies. Subsequently, propidium iodide (PI) (Life Technologies, Carlsbad, CA) 
was added to exclude dead cells. Cell analysis and sorting was performed on a FACS ARIA 
III or Fusion and data was analyzed using FlowJo v9.9. CLL cells were purified and sorted as 
the population with PI-CD11b/CD14/CD16/CD56-CD3-CD19+CD5+. Depending on the 
characteristics of different cell populations, normal B-cells, T-cells, NK cells and dendritic 
cells (DCs) were also sorted and analyzed. 
 
3.5.3 Proximity Extension Assay (PEA)   
Proximity Extension Assay (PEA) is a high throughput immunoassay for the detection of 
protein biomarkers in liquid samples. This method is performed by using 96x96 format 
(Olink Bioscience, Uppsala, Sweden)180. For each biomarker, unique oligonucleotides that 
used as probes are linked to a matched pair of antibodies, which bind to the respective 
targeted proteins. Subsequently, the probes hybridize and bind to each other. DNA 
polymerase is then added to promote an extension of the hybridizing oligo to obtain a DNA 
amplicon.  
In paper II, we used PEA to measure the biomarkers in plasma samples. Ninety-two 
inflammation-related biomarkers were investigated simultaneously. For each sample, 1 µl	of 
plasma was taken for each measurement and then duplicate measurements were run. 
Statistical analysis was performed to compare levels of the biomarkers at various timepoints 
during treatment with the levels at baseline.  
 
3.6 IDENTIFICATION OF NOVEL BTK VARIANTS IN XLA PATIENTS  
In paper III, we studied a large cohort of XLA patients and identified BTK mutations in these 
patient samples. 108 unrelated patients were collected and analyzed in Karolinska Institutet 
(KI) in Sweden. All the patients were males and diagnosed as carrying XLA. The diagnosis 
was made based on low levels of all isotypes of Igs, the very low levels or even absence of 
circulating B cells, and susceptibility to infections. Sanger sequencing was performed to 
detect the variations. The detailed information can be found in the previous publication44.  
 
 
 
 
 
 24  
 
 
 
 
 						
 
 
 
 25  
4 RESULTS AND DISCUSSION 
4.1 PAPER I 
Ibrutinib is the first approved BTK inhibitor, which shows high efficacy in CLL patients and 
is also the first BTK inhibitor to which patients have developed resistance. The most common 
resistance mechanism is cysteine-to-serine mutation at C481 site of BTK.  
In this study, we generated all the six possible BTK variants at Cys481 site and we also 
included one threonine variant since serine has similar function and structure with threonine, 
even though two nucleotide changes are required. Plasmids encoding BTK substitutions with 
C481F, C481G, C481R, C481S, C481T, C481W and C481Y were transfected into a non-
lymphoid cell line and all the variants were demonstrated to express equally and stably.  
In order to explore the relevance between the structure and the function of the variants, 
plasmids were transfected to both non-lymphoid cell line and BTK-deficient chicken B cells. 
The phosphorylation status at Y223 and Y551 of BTK and the catalytic activity of all the 
seven BTK variants were analyzed. We found that variants with either serine or threonine 
substitution retained catalytic activity, whereas the glycine variant displayed enzymatic 
activity but to a much lesser extent than serine or threonine replacement. Conversely, the 
phosphorylation of other four BTK variants was compromised severely and these variants 
could not phosphorylate PLCg2, which is a direct BTK substrate.  
C481 is a functionally essential site implicated in ATP binding and in the constitution of the 
catalytic conformation of BTK. The majority of amino acid substitutions at this position are 
predicted to be pathogenic both by PON-BTK and PON-P2 tolerance predictors44,181. In the 
BTK active conformation, C481 involves in the orientation of the catalytic R525. Since serine 
and threonine replacements can still form similar interactions as the original cysteine, these 
two BTK variants could be functional. For the variants with C481F, C481W and C481Y, the 
aromatic side chains of these amino acids are big and bulky, which results in structural 
conflicts within the kinase domain and the substrate. For the C481R variant, the arginine side 
chain is long and flexible, and while it can be accommodated to the structure, it is unable to 
form the catalytic conformation of BTK because of the charged side chain. However, BTK 
C481G variant showed activity since it does not contain any side chain and then the binding 
could be still allowed. This variant seems to have the right conformation but does not have 
functionally important side-chain interactions. 
To investigate the sensitivity of the active BTK variants to ibrutinib, the cell lines mentioned 
above were transfected with plasmids encoding BTK C481S or C481T variant and then  
treated with sequential concentrations of ibrutinib. In wild-type BTK, the activity of BTK 
was inhibited strongly with 0.5 µM ibrutinib, whereas the two active variants required much 
higher concentration of ibrutinib to block their activity. Moreover, ibrutinib washout 
experiments were performed and demonstrated that the activity of C481S and C481T variants 
could only be inhibited when they were incubated with high concentration of ibrutinib 
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continuously. Therefore, we concluded that in addition to C481S variant, the C481T 
replacement could also be one potential ibrutinib resistance mechanism. However, since the 
C481T variant needs two nucleotide changes, its occurrence is expected to be much lower 
than C481S variant. 
In addition, we also performed the modeling of the BTK kinase domain structure with 
ibrutinib. As described above, serine and threonine can maintain similar interactions as 
cysteine, thereby both variants are functional. They have an -OH end group instead of the -
SH group and contain electrostatic properties and hence form interactions. However, serine 
and threonine are incapable of forming covalent bonds with ibrutinib, which make them 
insensitive to ibrutinib. The C481G variant is unable to activate downstream signaling fully, 
and therefore it is not expected to be crucial for tumor cell survival during ibrutinib treatment. 
For those inactive BTK variants, we propose that they would hamper tumor cell survival 
since active BTK is essential for the growth of B-cell derived malignant cells. The ibrutinib 
sensitivity of all the variants and their effects on downstream signaling are summarized in the 
following figure 6. 
 
Figure 6. Schematic diagram of the BCR signaling pathway displays the sensitivity of BTK 
C481 variants to ibrutinib and their effects on downstream signaling182. 
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4.2 PAPER II 
As discussed previously, in CLL patients, ibrutinib is the first FDA-approved BTK inhibitor 
for therapy. Many patients with ibrutinib treatment have described that they had an nearly 
immediate sensation of improved well-being after the first dose of this drug. However, the 
reason for this clinical phenomenon is unclear. In this study, we characterized thoroughly of 
ibrutinib-induced changes at inflammatory, transcriptional and cellular aspects in both LN 
and PB samples immediately after the start of the treatment. We have compared the changes 
before treatment and after treatment in LN and PB, as well as the difference between LN and 
PB. 
We collected LN and PB samples before treatment and at 6 time points after treatment 
initiation, which are 9h, days 2, 4, 8, 15 and 29. Firstly, we assessed the inflammation-related 
biomarkers in plasma samples. Plasma was collected from PB and the levels of 92 
inflammation-related protein biomarkers was analyzed at pre-treatment and at 6 time points 
during the treatment. We found that the levels of 23 molecules were down-regulated more 
than one time points. To explore if the changes corresponded to the mRNA levels, we 
performed RNA-sequencing in CLL cells sorted from LN and PB. In plasma samples, the 
expression of CCL2, CCL3, CCL4, CCL19, IL-10, TGF-a and TNF-b was already decreased 
by 9h and continuously down-regulated throughout all the following time points. CCL3 and 
CCL4 are considered to be prognostic markers in CLL and our RNA-sequencing data 
propose that these two chemokines may mainly originate from CLL cells resident in LN. 
Most of the 23 molecules were found to be not expressed in sorted CLL cells, which 
suggested that ibrutinib might influence directly other BTK-expressed cells instead of B cells 
or CLL cells. The effect could also be on e.g., other kinases in these cells. For example, the 
downregulation of CCL2 is probably because ibrutinib affects monocytes, which are the main 
cell source of CCL2 production. In addition, the majority of the downregulated cytokines are 
pro-inflammatory, which is consistent with previous study demonstrating that inflammatory 
cytokines might prevent CLL cells from apoptosis both in vivo and in vitro 183.  
We also performed RNA-sequencing on the LN and/or PB samples before treatment, at day 2 
and day 29 to explore the entire effect of ibrutinib on RNA level. The levels of 357 genes was 
changed at day 2 after treatment initiation in CLL cells from both LN and PB. Next we 
looked into the function of the affected genes, and it showed that the upregulated genes were 
related to ribosome assembly and translation. Whereas, the genes downregulated were linked 
to B-cell proliferation, hematopoiesis, leukocyte cell-cell adhesion and regulation of kinase 
activity. In addition, the downstream molecules of BCR and NF-kB signaling, E2F and MYC 
target genes have been previously reported to be highly expressed in LN CCL cells from CLL 
patient184. The similar scenario occurred in our study, in which the levels of BCR, NF-kB and 
E2F target genes were significantly higher in LN CLL cells than in PB CLL cells. Ibrutinib 
treatment induced significantly decrease of BCR, NF-kB, E2F and MYC target genes in LN. 
However, in PB, only the BCR downstream genes showed continuous reduction after 
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treatment, while E2F and MYC target genes were only downregulated at day 2 after ibrutinib 
treatment.  
It is a common observation that ibrutinib treatment induces a rapid increase of ALC in CLL 
patients, which is called ‘redistribution lymphocytosis’. This phenomenon is due to the 
migration of lymphocytes from LN to PB after ibrutinib treatment, which is probably because 
ibrutinib affects some adhesion factors in LN157. We observed the same phenomenon that 
ALC was significantly increased at days 2, 8 and 15. In four CLL patients, the ALC 
decreased at day 29 probably because CLL cells without supported TME like LN went to 
apoptosis. However, circulating T-cells were not affected while the proliferating T-cells were 
reduced significantly at day 29.  
In addition, we assessed the changes of cell activation and migration markers between paired 
LN and PB samples during treatment. Only the expression of CD23, which is also a 
diagnostic marker in CLL, was found to be higher in LN than PB at baseline185. CD23 
expression was reduced from day 2 in LN, but was downregulated much later in PB, at day 
29. In healthy individuals, the interaction between CD23+ immature B-cells and T-helper 
cells could stimulate BCR signaling, which might cause autoimmunity186,187. After ibrutinib 
treatment, the early reduction of CD23 level in LN suggests that CD23 may be the most 
BCR-dependent CLL surface antigen as well as a good marker for the downregulation of 
BCR signaling. CD5, as a CLL marker, was highly expressed in LN CLL cells but was found 
to be downregulated only in CLL cells in PB at day 29. This may be because CD5 induces 
autoreactive B-lymphocyte tolerance, thereby restraining BCR activation and preventing cell 
expansion188,189.  
In CLL cells, the surface markers such as CXCR4 and CD49d are highly expressed, being 
important regulators for cell trafficking. In our study, both CXCR4 and CD49d were not 
decreased in PB and LN CLL cells. The interaction between CXCR4 and CXCL12 was 
suggested to be the mediator for CLL cell homing190. Our data indicated that the migration of 
CLL cells from LN to PB may be independent of CXCR4 downregulation in these patients.  
At day 29, we also observed the decrease of CD16+SLAN+ monocytes. This type of 
monocytes can secrete high levels of TNF-a. Consistent with the low SLAN expression in an 
XLA patient, which lacks functional BTK, our results suggest that the reduction of 
CD16+SLAN+ monocytes was associated with ibrutinib therapy. CLL cells or T-cells in TME 
also can secrete TNF-a to inhibit plasmacytoid dendritic cells (pDCs) development191. In our 
patients, no pDCs were detected in three of five patients and pDCs population was 
upregulated during treatment, which could be attributed to the reduction of TNF-a produced 
by CLL cells or T-cells in TME upon ibrutinib treatment.  
In conclusion, we demonstrated that ibrutinib treatment leads to a rapid interruption of an 
ongoing inflammatory response and impedes diverse pathways not only in CLL cells but also 
in TME, which mainly occur in LN. Moreover, we confirmed the association between BTK 
and chemokine synthesis, which might facilitate the development of therapy in future.  
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4.3 PAPER III 
BTK is an essential component in B-cell development and is important for the B-cell 
dependent tumor progression. Loss of function mutations in BTK cause the primary 
immunodeficiency disease, XLA. Therefore, BTK acts as an activator in both B-cell 
development and progression of BTK-dependent tumors.  
In this study, firstly we analyzed a large cohort of XLA patients and compared the mutation 
spectrum with those occurring in leukemia and lymphoma in order to investigate the role of 
BTK in different malignancies. We focused on amino acid substitutions of BTK in this 
project, in which three groups of malignancies, BTK-dependent, BTK-potentially-dependent 
and BTK-independent, were dissected. As mentioned in the previous chapters, BTK 
inhibitors have been FDA-approved to treat B-cell malignancies, such as CLL, MCL and 
MZL. Based on the published information, we found that no XLA-causing mutation was 
observed in a big number of CLL (n=1,115) and MCL (n=239), which is consistent with our 
hypothesis that these tumors are sensitive to BTK inhibitors so they should not have XLA-
type mutations167,172,192–197.  
Moreover, we studied amino acid substitutions in a large group of non-B-cell tumors from a 
mutation database198. There are 161 patients reported with amino acid replacements from 
10,086 patients. This data is used as a comparison in our study.  
The third group of tumors, are those hypothesized to be BTK-potentially-dependent, like 
DLBCL, FL and GC B-cell derived lymphomas. Since a subgroup of these tumors is 
sensitive to BTK inhibitors, XLA-type mutations should be selected against. Previously, it 
was proposed that BTK acted as a tumor suppressor by stabilizing p53 expression in vitro. 
Additional study displayed that lack of BTK expression promoted tumor formation in 
BLNK/SLP-65 deficient mice70. From our analysis, we found that the number of XLA-type 
mutations (the sum of known + predicted) was significantly higher than the number of such 
mutations in the non-B-cell tumors both if we considered the full-length BTK or only the 
kinase domain (P≤0.0005)195,198–201, which supported the hypothesis about the role of BTK as 
a tumor suppressor in BTK-potentially-dependent malignancy.  
In the large cohort of XLA patients analyzed in our study, six new amino acid substitutions: 
S38P, Y39H, F98L, V306D, R332L and H333L, of which R332L and H333L occurred in the 
same patient, were identified. Among them, three are new affected sites, S38, V306 and R332 
where no XLA mutations have been reported to date. Concerning the patient containing two 
mutations, R332L and H333L, the tyrosine substitution at H333 site has been identified to 
cause XLA, whereas the role of R332L is not clear. However, the SH2 domain recognizes 
pY-containing sequences as described previously and H333 was found to be involved in 
binding the pY-containing proteins. Therefore mutations at this site have high potential to 
cause disease202,203.  
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We have also performed predictions of the tolerance to every single amino acid replacement 
for the full-length BTK. In general, amino acid substitutions distribute throughout the whole 
BTK, except the SH3 domain where only two substitutions have been reported so far. In 
addition, there are some special regions without known XLA-causing variants or with several 
XLA variants. We chose three such sites, Q467, E599 and R618 in the kinase domain and 
generated a group of novel amino acid substitutions. Variants at these positions, which were 
predicted to be either neutral or pathogenic, were produced. The predicted neutral 
substitutions are Q467H, Q467L, E599K and R618K, and the predicted pathogenic 
replacements are Q467P, E599V and R618M. Their function was validated in vitro and the 
results were consistent with our predictions. For the variants predicted to be neutral, both 
BTK and PLCg2 were phosphorylated, which reveals that these amino acid substitutions 
indeed are tolerated.  
For the whole BTK, the solvent accessibility of each residue was explored and all amino 
acids were assigned to be exposed, buried or intermediate. We have made calculations about 
the tolerance of amino acid substitutions for each domain and we found that tolerance at 
buried positions is lower than exposed positions in the KD, which was the same as previously 
reported44. Similar scenario occurred in the PH domain, whereas not so obvious in SH2 
domain, since many exposed sites which are involved in the BTK structural formation, are 
highly mutated. Few mutation sites have been identified in the TH and SH3 domains so that 
we could not make any conclusion.  
In addition, amino acid replacements seem to be less tolerated in secondary structural 
elements, including helices and β-strands, than in loop regions. We have integrated the 
secondary structures of the whole BTK and investigated the substitution tolerance. Generally, 
amino acid substitutions occurred in higher frequency among the residues belonging to the 
helices (36.7%) and followed by β-strands (28.8%) as compared to the loop regions (24.2%). 
However, this phenomenon is not the same if we consider every single domain, suggesting 
caution for the evaluation of rare mutation sites, like the TH and SH3 domains, as discussed 
above. For malignancies, we observed that mutations are also highly tolerated in loop regions 
especially for the BTK-potentially-dependent cancers. 
In conclusion, we have studied the function of BTK in malignancies, and it seems that BTK 
acts as a tumor suppressor in the BTK-potentially-dependent cancers. To the best of our 
knowledge, in patients with hematopoietic malignancies, there has never been any clear 
evidence for the function of BTK as a tumor suppressor and this was addressed in this report.  
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5 CONCLUSIONS 
BTK is a crucial component in the BCR signaling pathway, which regulates B-cell survival, 
proliferation and differentiation. BTK mutations can be XLA-causing or be neutral, which 
depends on the alterations of the protein stability and function. For malignancies, BTK is 
activated in several lymphoma and leukemia cells. Therefore, BTK inhibitors, especially 
ibrutinib, have been developed rapidly and show high efficacy in patients. However, certain 
number of patients develop resistance to ibrutinib and the main mechanism is the cysteine-to-
serine mutation at C481 site of BTK, to which ibrutinib binds. In the paper I, we 
demonstrated another potential resistance mechanism, which is the cysteine-to-threonine 
mutation at C481 position. In paper II, the very early effects of ibrutinib in CLL patients have 
been investigated. Our data illustrated that ibrutinib affected the expression of several 
chemokines as early as 9h after treatment initiation. In addition, RNA-sequencing results 
indicated that ibrutinib significantly downregulated the levels of BCR, NF-kB and E2F target 
genes, which are associated with CLL cell survival and proliferation. Moreover, ibrutinib 
affected other cell populations, such as CD16+SLAN+monocytes. Therefore, the improved 
well-being of CLL patients treated with ibrutinib is due to the comprehensive effects of 
ibrutinib not only on B-cells but also on other cell populations and chemokine or cytokine 
synthesis. In paper III, we have compared the germline mutations of a large number of XLA 
patients with the acquired mutations in BTK-potentially-dependent tumors. The data suggests 
that BTK acts as a potential tumor suppressor in a subset of this group of malignancies. The 
conclusions of the three papers are summarized as shown in Figure 7. 
Figure 7. Schematic representation of summarizing the three papers. 
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